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Estimating future health technology diffusion using expert beliefs calibrated to an established 
diffusion model  
 
Abstract  
Objectives: Estimates of future health technology diffusion, or future uptake over time, are a requirement for 
different analyses performed within health technology assessments. Methods for obtaining such estimates 
include constant uptake estimates based on expert opinion or analogous technologies, and extrapolation from 
initial data points using parametric curves ± but remain divorced from established diffusion theory and 
modelling. We propose an approach to obtaining diffusion estimates using experts¶ beliefs calibrated to an 
established diffusion model to address this methodological gap. 
Methods: We performed an HOLFLWDWLRQRIH[SHUWV¶EHOLHIV on future diffusion of a new preterm birth screening 
illustrative case study technology. The elicited quantities were chosen such that they could be calibrated to yield 
the parameters of the Bass model of new product growth, which was chosen based on a review of the diffusion 
literature.  
Results: With the elicitation of only three quantities per diffusion curve, our approach enabled us to quantify 
uncertainty about diffusion of the new technology in different scenarios. Pooled results showed that the 
attainable number of adoptions was predicted to be relatively low compared with what was thought possible. 
Further research evidence improved the attainable number of adoptions only slightly but resulted in greater 
speed of diffusion. 
Conclusions: 7KHSURSRVHGDSSURDFKRIHOLFLWLQJH[SHUWV¶EHOLHIVDERXWGLIIXVLRQDQGLQIRUPLQJWKH%DVVPRGHO
has the potential to fill the methodological gap evident in value of implementation and research, as well as 
budget impact and some cost-effectiveness analyses. 
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Highlights 
Estimates of future health technology implementation are a requirement for different analyses performed within 
health technology assessments (HTAs). Methods for obtaining such estimates have included simple uptake 
estimates held constant over the time horizon based on expert opinion or analogous technologies ± but remain 
divorced from established diffusion theory and modelling. 
This SDSHUDGGVDQHZDSSURDFKWRREWDLQLQJGLIIXVLRQHVWLPDWHVXVLQJH[SHUWV¶EHOLHIVFDOLEUDWHGWRDQ
established diffusion model to address this methodological gap. This approach can help inform value of 
implementation and research, as well as budget impact and cost-effectiveness analyses, which are increasingly 
relevant in HTA decision-making. 
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1. Introduction 
 
Estimates of health technology uptake, or diffusion when considered over time, are of increasing importance in 
health technology assessment (HTA) decision-making. The definition of uptake, for the purposes of this article, 
is the number of units of a technology purchased through the health system relating to a specific medical 
indication. Diffusion is defined as the process of uptake growth over time (1). For instance, numerous studies 
are performed to assess the value of implementation measures (2-7), for which both the potential diffusion with 
the implementation measure and the counterfactual (what happens if we opt to not invest in implementation) are 
needed (7, 8). In budget impact analyses, the requirement for an estimate of the affected population also 
necessitates an estimate of the likely market share or uptake of a new technology, preferably of dynamic nature 
(9, 10). In cost-effectiveness analyses, recent research showed that prices of medical devices may decline with 
increasing uptake and this mechanism was implemented in a cost-effectiveness framework that enabled the 
assessment of dynamic cost-effectiveness and price-volume agreements (1, 11). Finally, value of research 
studies have investigated the potential effect of research on diffusion, and highlighted that quantification of the 
effect of research on diffusion enables better estimation of the value of research (12, 13). These HTA themes 
thus have in common that diffusion estimates are often required for their appropriate consideration.  
 
Existing studies using uptake estimates within HTA have relied heavily on the use of constant uptake estimates, 
based on similar technologies or expert opinion (14). Alternatively, parametric curves were used to inform 
dynamic uptake curves (2, 3). The issue with the first approach is that health technology uptake is unlikely to be 
best represented by a single uptake estimate held constant across future time periods, as was shown in empirical 
evidence from many different countries (15). A literature review concluded that uptake generally varies over 
time and is heterogeneous at therapeutic class level as well as at the technology level (7). The second approach, 
extrapolating future diffusion from available data points, suffers from two issues: first, fitting parametric curves 
through a few data points can result in vastly different diffusion patterns, because these curves do not typically 
account for a likely ceiling value or the speed of diffusion based on diffusion theory insights. More sophisticated 
methods of extrapolating diffusion from existing data are available in the forecasting literature (16, 17). Second, 
HTA decision-making requires the diffusion estimate to be available prior to the launch of the technology, 
creating many situations in which uptake estimates for a technology in question are not available. In summary, 
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there is a need for methods that help predict technology uptake prior to technology introduction, and that allow 
estimation of diffusion, rather than constant uptake rates. 
 
We therefore reviewed the forecasting and diffusion literature in search for methods to estimate diffusion prior 
to technology introduction. Diffusion theory was established by Rogers in 1962, suggesting that diffusion of 
goods typically follows an s-shaped curve, time being presented on the x-axis and cumulative per period uptake 
on the y-axis (18). The s-shape resulted from the assumption that populations are heterogeneous in their 
propensity to innovate, with innovators having a relatively small threshold to technology adoption and imitators 
having a relatively higher threshold (16). Rogers assumed that the threshold sizes were distributed normally 
among the population (18).   
 
It furthermore became evident that there is a limited number of tools available to researchers who wish to 
predict diffusion prior to technology introduction, called pre-launch forecasting in the diffusion literature (17). 
The two methods typically used for pre-launch forecasting DUH³JXHVVLQJE\DQDORJ\´ and subjective judgements 
(17). Guessing by analogy involves (a) choosing technologies that can be considered as analogous by using pre-
specified criteria and (b) using available time series data for the analogous technologies to predict sales of the 
new technology (19-21). In health care, such guessing by analogy applications appear to be limited to estimates 
of constant uptake. Limitations associated with this approach include that little is known on how analogies 
should be chosen (19), the unavailability of similar products in certain technology types (20), selection bias 
caused by diffusion data of unsuccessful products rarely being available (20) and elapsed time since the 
analogous technology was introduced, which may have brought about other exogenous factors influencing 
diffusion patterns (22).  
 
Compared to guessing by analogy, subjective judgement methods provide the advantage of enabling experts to 
consider technology- and time-specific conditions. However, published studies typically fail to quantify the 
uncertainty associated with the forecasts and do not use the structure of formal diffusion models (17). Without 
an assessment of uncertainty, resulting forecasts are of limited use to decision-makers. The use of approaches 
that do not use a formal forecasting model also introduces bias (17).  
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We conclude that the requirement for diffusion estimates at the time of HTA stands in stark contrast to the 
dearth of methods permitting an estimation of diffusion in accordance with diffusion theory available to health 
economic analysts at present. In this paper, we therefore aim to develop a novel approach to estimating diffusion 
of health technologies using a formal process of elicitation of expertV¶ beliefs, and calibrating these to an 
established diffusion model. Given the complexity of the topic, we see particular value in a detailed methods 
guide for interested researchers. We illustrate our approach in a case study on a preterm birth screening 
technology. The paper is structured as follows: we first present the diffusion model in the Methods Section 2.1, 
then propose an approach to estimating this by eliciting observable quantities and calibrating these (Section 2.2). 
We describe background on the case study technology (Section 2.3) and provide more detail on the elicitation 
study (Section 2.4). In Section 3, we present results of the application in the illustrative example, and we 
provide a Discussion and Conclusion in Sections 4 and 5. 
 
2. Methods 
 
2.1 The diffusion model  
 
The most widely cited model for diffusion of innovations is the Bass model of new product growth (16), which 
represents the sigmoid shape of diffusion first proposed by Rogers (18). For short the Bass model, it was 
developed in 1969 (23) DVDQDGDSWDWLRQRIDORJLVWLFPRGHOWKDWUHIOHFWVWKHHIIHFWVRIµLQQRYDWLRQ¶DQG
µLPLWDWLRQ¶WREHFRQVLVWHQWZLWKGLIIXVLRQOLWHUDWXUH(18):  
 
 ܲሺݐሻ ൌ ݌ ൅ ݍ כ ௧ܰିଵ݉  (1)  
Where P(t) is the probability of adoption in period t, p the coefficient of innovation or external influence, q the 
coefficient of imitation or internal influence, m the number of attainable adoptions, and ௧ܰିଵ the number of 
cumulative adoptions up to the previous period t-1.  
 
This equation is commonly re-arranged to yield the number of adoptions in period t:  
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 ݊௧ ൌ ݌ሺ݉ െ ௧ܰିଵሻ ൅ ݍ ௧ܰିଵ݉ ሺ݉ െ ௧ܰିଵሻ (2)  
Where ݊ݐ is the number of per period adoptions in period t. 
 
To give an intuition about these parameters, note first that the number of attainable adoptions m does not 
necessarily coincide with any normative idea of what the maximum number of potential adoptions could be. 
Second, equation (1) shows that if ݍ ൌ Ͳǡ ܲሺݐሻ ൌ ݌ across all periods t, which means that imitation plays no role 
in the diffusion of the technology and the probability of adoption in a period stays constant. If ݌ ൌ Ͳ, however, 
imitation factor q solely dictates the speed by which the attainable number of adoptions is reached by 
determining the proportion of the remaining ሺ݉ െ ௧ܰିଵሻ non-adopters that will adopt in period t. The term ݌ ൅ݍ controls the scale and the term ௤௣ controls the shape of the diffusion curve, with ௤௣ ൐ ͳ ensuring the s-shape of 
the cumulative diffusion curve. Parameters p and q are therefore interdependent. Reported ranges for parameters 
p and q from a meta-analysis of diffusion curves in a variety of industries were (0.000021; 0.03297) and 
(0.2013; 1.67260) respectively (24). 
 
2.2 Eliciting beliefs about diffusion 
 
The Bass model parameters are not straightforward to elicit because they are not observable quantities (25, 26) ± 
expressing an opinion about the value of the coefficients of innovation or imitation is cognitively challenging. 
Another challenge is to keep the elicited summaries to a particular type rather than eliciting a mix of absolute 
numbers, proportions and odds ratios (27).  
 
Given these challenges, our proposed solution is to elicit uncertainty about the following three quantities: the 
attainable number of adoptions (which we denote as m), the number of adoptions in the first year after 
technology introduction (denoted as N1), and the point of inflection, described as the number of years after 
which the number of adoptions starts to decline (W¶). The elicited quantity m is equivalent to the Bass model 
parameter m, whereas quantities N1 and W¶ require further computation to generate the Bass model parameters p 
and q. Unfortunately, there is no simple algebraic solution that converts observable quantities into Bass model 
parameters. Kim, Hong (22) found algebraic solutions for the logistic model but not for the Bass model. 
However, the logistic model cannot reflect asymmetrical diffusion curves. Another study found an algebraic 
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solution for quantities that we considered less intuitive, such as the sum of Bass model parameters p and q (28). 
Instead, we used a numerical approximation using minimisation of the sum of squared error terms on the three 
elicited quantities. This entailed using excel solver to calculate the error terms between the elicited information 
and the fitted diffusion curve in each solver trial run until the sum of squared error terms was minimised. The 
computation of parameter values was performed for 1,000 random samples from the probability distributions of 
the three elicited quantities to yield distributions of parameters p and q.  
 
A problem associated with estimation of parameters in the classic Bass model is that it can result in an 
XQUHDOLVWLFµRVFLOODWLQJ¶FXUYHat specific combinations of parameters p and q because of its time-continuous 
presentation of discrete data. This arose as a consequence of simplifying the process for the experts by eliciting 
parameter values independently and ignoring the correlation between uncertain parameters. To overcome this 
feature, we used the Satoh adaptation of the Bass model (29), which applies a discrete analogue of a quadratic 
first order equation to the Bass model to make it discrete in time rather than continuous in time, such that: 
 
 
௧ܰ ൌ ݉ۉۈ
ۇ ͳ െ ൬ͳ െ ሺݍ ൅ ݌ሻͳ ൅ ሺݍ ൅ ݌ሻ൰௧ଶͳ ൅ ݍ݌ ൬ͳ െ ሺݍ ൅ ݌ሻͳ ൅ ሺݍ ൅ ݌ሻ൰௧ଶیۋ
ۊ
 (3)  
 
where ௧ܰ is the cumulative number of adoptions in period t. 
 
2.3 Background on the case study technology  
 
The illustrative case study technology is a new device that can help determine whether a pregnant woman is 
likely to have a preterm birth. This device is still in development and accuracy data are confidential. Compared 
to the existing standard option, an early study showed that the new technology would be more sensitive and 
more specific. However, sensitivity was still considered relatively low. The new technology would be easy to 
use, address capacity issues with the existing technology, its purchase would not be exceedingly costly, but it 
would be associated with some consumable cost. Treatment options if tested positive include progesterone and 
cervical cerclage. There were 231 obstetric units in England, which would be expected to purchase one or more 
devices each (in order to ensure simultaneous use and back-up).  
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2.4 Elicitation of expertV¶ beliefs about the diffusion curve of the new preterm birth screening technology 
 
Elicitation of expertV¶ beliefs is a widely-XVHGPHWKRGWRREWDLQTXDQWLWDWLYHH[SHUWV¶MXGJHPHQWVUHIOHFWLQJ
parameter uncertainty (25),WGHVFULEHV³the process of capturing expert knowledge about one or more 
XQFHUWDLQTXDQWLWLHVLQWKHIRUPRIDSUREDELOLW\GLVWULEXWLRQ´(30). Structured approaches to elicit expertV¶ 
beliefs have been found to reduce bias (26) and tools and software packages are readily available, for example, 
the Sheffield Elicitation Framework (SHELF) (30). Structured elicitation of expertV¶EHOLHIV requires thorough 
preparation and consideration of many aspects that require a methodological choice by the analyst (31, 32). We 
briefly summarise the main decisions in the following, according to reporting guidelines for use of expert 
judgement (32). More detail can be found in the elicitation protocol in the appendix and the R package on the 
SHELF website (30).  
 
We recruited three obstetricians from different locations and types of hospitals in England. In order to qualify 
for the study, they had to fulfil criteria of having a tangible level of expertise, an understanding of the general 
problem area, and no conflict of interest. Tangible expertise required that experts had knowledge about the 
therapeutic area (preterm birth), treatment and diagnostic options in the area, and were familiar with the 
commissioning process of new health technologies. Obstetricians practicing in English hospitals were 
considered generally eligible for the reasons that: 1) diffusion for the preterm birth screening technology was 
limited to patients in England for this illustrative example; 2) in England, the technology would be made 
available to hospitals with obstetric units that assess women at high risk of preterm birth; and 3) the key 
customers are obstetricians, typically involved throughout the procurement decision-making process. The 
H[SHUWV¶deeper tangible expertise was established within a preceding qualitative study.  
 
Possible biases and heuristics were discussed and experts encouraged to avoid these. Training of experts should 
involve following the process of elicitation through for a quantity that is unknown to the experts but knowable 
in principle (25). For this, the number of preterm births in England was elicited from each expert, using a scalar 
quantity in keeping with the quantities elicited in the main study. We used the tertile method, a variable interval 
method in which experts are asked about the median of an uncertain quantity, ܺ, say, such that ݌ሺܺ ൏݉݁݀݅ܽ݊ሻ ൌ ͲǤͷ, and then the first and third tertiles such that ݌ሺܺ ൏ ݐଵሻ ൌ ͳ ͵ൗ  and ݌ሺܺ ൏ ݐଷሻ ൌ ʹ ͵ൗ , 
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respectively. Separate face-to-face sessions were held with each expert and gamma distributions fitted to their 
elicited values. The distributions were then combined across experts using linear mathematical pooling, with 
equal weights for the experts. One pilot was performed, and no changes were made to the protocol subsequently.  
 
Within the provision of background information, experts were provided a document with general background on 
preterm birth statistics, the accuracy data of the new and the current technologies and other information 
mentioned in Section 2.3, a brief background on diffusion theory, and a presentation of findings from the 
preceding qualitative study, which suggested that further research would be desirable to establish the predictive 
accuracy of this technology. We therefore performed the elicitation exercise twice: once for a scenario based on 
the current evidence of predictive accuracy, and once more for a hypothetical scenario in which new evidence 
on the device¶VDFFXUDF\ was available. We provide a view to the mechanism by which any change in diffusion 
FRXOGEHDWWDLQHGZLWKWKHDYDLODELOLW\RIIXUWKHUUHVHDUFKHYLGHQFHE\UHSRUWLQJH[SHUWV¶UDWLRQDOHVIRUWKHLU
estimates of the ³with research´ diffusion curve. These qualitative statements were obtained as part of one of the 
steps in SHELF, fitting the distribution and feedback. 
 
3. Results 
 
In summary, the pooled elicitation results (Tables 1 and 2, Figure 1) suggest that the maximum attainable 
number of adoptions for the preterm birth screening device in England will be at 140 devices without further 
research and at 146 with further research evidence. These are relatively small numbers given that there are 231 
obstetric units in England and that most units would be expected to purchase more than one device. A very 
small number of adoptions would occur in the first year, at a mean of six adoptions, or thirteen adoptions with 
the availability of more research evidence. The rationale given by the experts was that in the first year, potential 
purchasers would mainly be hospitals that were involved in the development of the technology or those that had 
research grants for it (Table 3 and Figure 2). The number of years at which the maximum number of per-period 
adoptions is reached was estimated to be at a mean of six years, or five years with more research, with the 
rationale being that a greater evidence base would enter the consciousness of clinicians sooner.  
 
To provide an overview of the individuaOH[SHUWV¶EHOLHIV7DEOH3 and Figure 2 present the results for each 
expert. Expert 1, who predicted the flattest GLIIXVLRQFXUYHWKRXJKWWKDWWKHGHYLFH¶Vaccuracy was not 
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convincing. Expert 2 had similar reservations but considered that more evidence, even showing the same result, 
would help with the evaluation process. Expert 3 thought that the maximum number of adoptions was 
constrained by the adversity to innovation in the England National Health Service (NHS) but they thought that 
the device would diffuse quickly within these constraints and that further evidence would speed up the diffusion 
process slightly.  
 
Computing the distributions of p and q from the elicited distributions resulted in mean values of 0.031 and 
0.472, respectively, for the current scenario and 0.058 and 0.543, respectively, for the further research scenario 
(Table 1). The exact p and q values lack an intuitive interpretation but can be interpreted in the context of the 
general statements outlined in Section 2.1 of this paper. Uncertainty about the shape of the ³without evidence´ 
diffusion curve is presented in Figure 3, in which the mean diffusion curve is plotted along with the curves 
obtained when the 95% credible interval values of parameters p, q and m are used. 
 
4. Discussion 
 
In this paper, we have presented a novel approach to predicting diffusion of new health technologies using 
HOLFLWDWLRQRIH[SHUWV¶EHOLHIVabout uncertain values to inform an adaptation of the Bass model of diffusion. We 
applied our approach to estimating diffusion of a new preterm birth screening technology for two counterfactual 
scenarios of with and without the availability of further research evidence. Pooled results showed that the 
attainable number of adoptions was predicted to be below what was thought to be possible for a new device in 
this therapeutic area. This was mainly attributed to relatively unconvincing accuracy evidence for the device and 
the general adversity to change that was thought to be present in the England NHS. The availability of further 
research evidence could improve the maximum attainable number of adoptions only slightly but resulted in 
greater speed of diffusion.  
 
The method presented in this paper is of particular relevance considering the lack of methods in the literature 
that addresses the requirements for dynamic estimates of technology implementation in the context of different 
types of analyses commonly performed within HTAs. More practically, the elicited diffusion curves for the new 
case study technology can inform further studies on the value of implementation of the collection of further 
research evidence, which can potentially speed up diffusion (12). Budget impact analysis could be performed 
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with these estimates. In value of research studies, the impact of collecting further research evidence can be 
assessed in terms of both the increase in implementation and the decrease of uncertainty. Finally, cost-
effectiveness of this technology could be modelled including price-volume agreements and the uncertainty about 
diffusion could be appropriately reflected in the probabilistic sensitivity analysis. Our paper offers an approach 
to obtaining the technology-specific and probabilistic diffusion estimates required for these analyses prior to 
technology introduction, a currently unexplored topic (17). The approach presented here improves upon the 
commonly used methods of using data from analogous technologies and deterministic expert or analyst 
judgements by providing estimates that reflect uncertainty about diffusion based on a widely validated diffusion 
model.  
 
The strength of this approach lies in the ability to estimate diffusion for the technology lifetime from only three 
elicited quantities. Our approach also enables the use of available expert knowledge, rather than being 
dependent on diffusion data for other technologies. Data on analogous health technologies are sparse, amongst 
others because of patent protection leading to long lags until competitors can enter the market. The Bass model 
of diffusion was chosen because of a strong evidence base in support of its ability to predict diffusion well in 
different industries. No other models had the same evidence base. Another strength is the elicitation of 
uncertainty information, with tKHSRVVLEOHµGLIIXVLRQVSDFH¶LQFOXGing a range of possibilities for different paths 
of diffusion that could become reality given that certain events occur (such as a new competitor entering the 
market).  
 
It may be perceived as a limitation that relatively little information is provided on our illustrative case study. We 
felt that a focus on the new approach was more appropriate. We wish to highlight that the choice of experts, the 
avoidance of heuristics and bias in elicitation, and the appropriate briefing on the technology and possible 
influencing factors and future developments deserve more attention and refer the reader to the wider elicitation 
literature (25-27, 31-33). The number of experts used should furthermore be carefully assessed. We used 3 
experts and thought this was possibly sufficient to characterise the uncertainty about future diffusion. However, 
Grigore et al. since then suggested between 6 and 12 experts (31), and hence, the use of only 3 experts may be a 
limitation. A technical limitation is that we univariately elicited beliefs about quantities that are likely to be 
interdependent. This, and the use of the Satoh adaptation of the Bass model, may have led to the introduction of 
bias that we were unable to quantify.  
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Alternative methodological choices in the elicitation of expert opinion include fixed interval methods such as 
the roulette method, which divide the sample space into fixed intervals and ask for the probabilities of these (27, 
34). Variable interval methods (such as the tertile method used here), in contrast, offer more flexibility for the 
expert but may sacrifice simplicity and there is no conclusive evidence on which method performs best (35). 
Another method is the so-called hybrid, in which experts are asked to provide information about the lowest and 
highest possible value as well as the most likely value of a quantity of interest (36).  
 
Alternative distributions could be used for the quantities of interest. In particular, where the number for 100% of 
adoptions is known (i.e. where there is an upper bound to uptake), it may be easier for experts to think about 
proportions of adoptions. More research is required to establish whether this would be the case and whether the 
elicited quantities could then easily be back-calculated to estimate the diffusion model parameters.  
 
There is no consensus on whether behavioural or mathematical aggregation of expert opinions should be used. 
Whilst behavioural aggregation through discussion and adjustment of beliefs in a group setting offers the 
advantage that a consensus can be found, this method also tends to produce over-confident judgements (27). 
Mathematical aggregation, however, neglects the different opinions of the experts. Due to time constraints, we 
were unable to perform a feedback round, in a technique that is known as the Delphi method and has previously 
been applied to forecasting (37).  
 
It should be highlighted that researchers performing such an exercise may wish to be careful in the study design 
to avoid any anchoring bias between scenarios. In our µZLWKUHVHDUFK¶ scenario, the newly generated hypothetical 
evidence was conditional on the currently existing evidence and we therefore did not perceive any anchoring as 
problematic. But when independent scenarios are elicited, a timely separation of the elicitation exercises is 
advisable to avoid anchoring. 
 
Alternative diffusion models may be used. The applicability of diffusion theory to health technologies may be 
compromised by health technologies being subject to different rules and adoption mechanisms compared to 
technologies in other industries. Other prediction models should arguably be tested in comparison with the Bass 
model, to assess their performance in predicting diffusion in the health technology sector.   
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Scope for further research includes applying our approach to more technologies. Its performance in accurately 
forecasting diffusion in comparison with other forecasting methods should be assessed once sufficient empirical 
data becomes available. Methodological research is furthermore required in elicitation techniques, in particular 
multivariate elicitation of interdependent quantities. 
 
5. Conclusion 
 
7KHSURSRVHGDSSURDFKRIHOLFLWLQJH[SHUWV¶EHOLHIVDERXWGLIIXVLRQDQGLQIRUPLQJWKH%DVVPRGHOKDVWKH
potential to fill the methodological gap evident in predicting diffusion for use in value of implementation and 
research, as well as budget impact and cost-effectiveness analyses. This approach may be useful to analysts 
wishing to consider technology-specific diffusion and to formally represent the associated uncertainty. 
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Table 1. Pooled elicited quantities and Bass model parameters  
    Without further research With further research 
Variable Mean  SD Median CI Variable Mean  SD Median CI 
m 140 69 128.84 (39-304) m 146 66.1 136.16 (46-301) 
n1 4.99 2.04 4.71 (1.8-9.7) n1 10.5 4.12 9.96 (4.0-20) 
t' 6.26 1.34 6.16 (3.9-9.1) t' 5.21 1.52 5.06 (2.7-8.6) 
Without further research With further research 
Bass model 
parameter Mean SD Median CI 
Bass model 
parameter Mean SD Median CI 
p 0.031 0.02 0.026 (0.005-0.083) p 0.058 0.038 0.049 
(0.013-
0.157) 
q 0.472 0.176 0.482 (0.2-0.806) q 0.543 0.136 0.524 (0.313-0.826) 
Key: m - number of attainable adoptions, n1 - number of adoptions in period 1, t' - time at which number of adoptions 
starts to decline, SD - standard deviation, CI - credible intervals 
 
Table 2. Cumulative adoptions as per 
pooled elicited diffusion curves 
  Nt 
Year 
Without 
research  
With 
research  
1 6 13 
2 15 33 
3 29 59 
4 47 87 
5 67 110 
6 87 126 
7 104 135 
8 117 140 
9 126 143 
10 131 145 
11 135 145 
12 137 146 
13 138 146 
14 139 146 
15 139 146 
16 140 146 
17 140 146 
18 140 146 
19 140 146 
20 140 146 
Key: Nt - cumulative number of 
purchases in period t 
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Table 3. Experts' individual elicited quantities 
    Expert  1 2 3 
Elicited quantity Mean 95% CI Mean 95% CI Mean 95% CI 
m - without research  54.2 (10-150) 158.8 (30-230) 204.4 (30-410) 
m - with research  68.7 (20-150) 174.2 (60-250) 204.4 (30-410) 
n1 - without research  2.3 (0-5) 5.7 (2-15) 7.1 (2-10) 
n1 - with research  2.3 (0-5) 5.7 (2-15) 23.7 (10-40) 
t' - without research  5.1 (3-8) 9.9 (7-13) 3.5 (2-6) 
t' - with research  5.1 (3-8) 8.2 (5-11) 2.6 (1-5) 
Key: m - number of attainable adoptions, n1 - number of adoptions in period 1, t' - time at which 
number of adoptions starts to decline, CI - credible interval 
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Figures 
Figure 1. Diffusion with and without further evidence collection 
 
 
Figure 2. Diffusion curves and justifications elicited from different experts 
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Figure 3. Uncertainty about "without further evidence" diffusion curve 
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Appendix 
Quantifying factors that will influence usage of a new technology for pre-term birth 
screening in the UK 
 
Script 
 
1. Introduction 
 Introduce yourself 
 Explain that the aim is to quantify beliefs about future purchases of Technology A for PTB 
screening in the UK 
 Explain that this study will inform an economic model  
 Explain that this is part of a PhD study that looks into how adoptions affect the evaluation of 
a technology  
 Explain that I wish to develop a standard approach by which experts are being asked about 
adoption of innovative technologies 
 Explain that this study is a so-called elicitation of expert beliefs by which experts quantify 
their opinions about some unknown quantities of interest  
 Explain that having a feeling of uncertainty with their opinion is fine and can be addressed 
using this method 
 Reassure re: confidentiality and anonymity. 
± Highlight that no individual will be identified. 
 Remind about length of meeting ± approximately 1 hour 30 mins 
 Check if participant has any questions at all at this stage 
 Ask participants to sign consent form to provide written consent for participation 
 Thank the participants for agreeing to participate 
2. Training 
 Explain that we will now conduct training using one example quantity that is not used for this 
study 
 Explain that we will elicit beliefs about the number of pregnant women delivering their baby 
pre-maturely in England, called X in the following 
 Refer to number of hospital births under bullet point 1. in background document as a help and 
tabular overview of how percentages translate to numbers 
 Provide calculator and sheet of paper 
 [R: Change dir Æ 'HVNWRSWKHQVRXUFH³VKHOI5´@ 
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 Ask experts to provide a range such that it is extremely unlikely but not entirely impossible 
that X falls outside that interval (lower bound L to upper bound U) [tertile.single(Lo=X1, 
Up=X2)] 
 Ask experts to state the median M, a number at which it will be as likely for X to be larger 
than the median as smDOOHUWKDQWKHPHGLDQ7KLVLVDYDOXHVXFKWKDWWKHSURSRVLWLRQWKDWµ;
OLHVEHORZWKHPHGLDQ¶LVHTXDOO\OLNHO\WRµ;OLHVDERYHWKHPHGLDQ¶ 
 Ask experts to state upper and lower tertiles (T1 and T2) by considering the range from L to 
U and dividing it into three equally likely intervals.  
± Point out that of course M will have to lie between T1 and T2.  
± Point out that this is like giving an interval at which they are 33% confident that X 
will fall into it 
± Ask experts to regard each of the three ranges (L to T1, T1 to T2 and T2 to U) as 
equally likely. 
± Ask experts to regard also as equally likely the ranges T1 to M and M to T2. 
± Point out that values of X close to M are likely more probable than values of X close 
to L and U, that is the intervals T1 to M and M to T2 will be narrower than the 
intervals L to T1 or T2 to U.  
 When tertiles are decided on, show histogram and ask whether they think that the 3 boxes are 
indeed equally likely [press show histogram] 
 Then show the fitted distribution (gamma) as density function [press first gamma, then 
density] and tell them their estimated mean 
 Reveal real results of number of pre-mature births in England (2011-2012): 42,000 which is 
equal to 6.3%. 
 
3. Structuring 
 Remind of background that was sent in advance of the meeting  
 Ask whether they want to go briefly through the explanation of Technology A in background 
doc (point 2) 
 Explain study results 
 Present LRs and sensitivity, specificity 
 Explain about uptake using the background document (point 4) 
 Explain 3 different uptake curves 
 ([SODLQWKDWWKLVPHDQVHOLFLWDWLRQRIPQDQGW¶ 
 ([SODLQWKDWODWHUZHZLOOORRNDWPQDQGW¶XQGHUWKHDVVXPSWLRQWKDWIXUWKHUWULDOVKDYH
been conducted 
 Highlight that in total we will elicit 6 quantities (if time permits) 
 Fill in expertise and declaration of interests in form 1 
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4. Elicitation 
 Explain that the first quantity to be elicited is the number of Technology A devices sold 
across all obstetric units in England (m1). 
 Remind them that they can use the information in point 1-4 from the background sheet. 
 
 For  m1: the number of Technology A devices potentially sold across all obstetric units 
in England 
 Ask experts to provide a range such that it is extremely unlikely but not entirely impossible 
that m1 falls outside that interval (lower bound L to upper bound U). 
[tertile.single(Lo=L,Up=U)] 
 Double-check by asking whether they really think that there is 0% chance that m1 will fall 
outside this range. 
 Ask experts to state the median M, a number at which it will be as likely for m1 to be larger 
WKDQWKHPHGLDQDVVPDOOHUWKDQWKHPHGLDQ7KLVLVDYDOXHVXFKWKDWWKHSURSRVLWLRQWKDWµP
lies below the mediaQ¶LVHTXDOO\OLNHO\WRµPOLHVDERYHWKHPHGLDQ¶[write down on 
Elicitation part 2] 
 Ask experts to state lower and upper tertiles (T1 and T2) by considering the range from L to 
U and dividing it into three equally likely intervals.  
± Point out that of course M will have to lie between T1 and T2.  
± Point out that this is like giving an interval at which they are 33% confident that m1 
will fall into it 
± Ask experts to regard also as equally likely the ranges T1 to M and M to T2. 
± Point out that values of m1 close to M are more probable than values of m1 close to L 
and U, that is the intervals T1 to M and M to T2 will be narrower than the intervals L 
to T1 or T2 to U.  
 Record median and tertiles in Elicitation part 2. 
 When tertiles are decided on, show histogram and ask whether they think that the 3 boxes are 
indeed equally likely [press show histogram] 
 Then show the fitted distribution (gamma) as density function [press first gamma, then 
density] and tell them their estimated mean 
 Ask whether experts are happy with their own distribution or whether they would like their 
judgements changed (tell them mean and 90% percentiles) 
± Record any changes in Elicitation part 2 - Fitting 
 Ask experts to individually explain their rationales for their distributions. 
 Record chosen distribution in Elicitation part 2, including median, tertiles and distribution. 
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 Then elicit (according to the same protocol):  
 n1-1: the number of purchases of Technology A in hospitals in first year 
 
 W¶WKHQXPEHURI\HDUVDWZKLFKWKHSXUFKDVHVper period peak 
 
 m2: the number of potential purchases of Technology A given new evidence  
 
 n1-2: the number of purchases of Technology A in first year given new evidence  
 
 W¶WKHQXPEHURI\HDUVDWZKLFKWKHSXUFKDVHVSHUSHULRGSHDNJLYHQQHZHYLGHQFH 
 
 
5. Conclusion 
 Highlight that this work will enable the preliminary economic evaluation of Technology A in 
PTB screening, including setting research priorities.  
 
Thank the participants for their time and contribution 
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Quantifying uptake determinants of Technology A for use in pre-term birth 
screening in the UK 
Elicitation briefing notes 
The purpose of the elicitation meeting is to obtain probability distributions to represent your 
uncertainty about various quantities of interest. These are listed in section three of the 
attached pro forma. 
The elicitation will be conducted following the Sheffield Elicitation Framework (SHELF), 
EDVHG RQ HOLFLWDWLRQ SUDFWLFH UHFRPPHQGHG LQ 2¶+DJDQ HW DO  <RX ZLOO EH JLYHQ
training in the process of elicitation at the start of the meeting, which will include a practice 
exercise to familiarise you with the procedure. 
It is important to note that you will not be asked to provide single estimates of any of these 
quantities. The elicitation process will instead involve considerations such as what a 
plausible range of values would be for each unknown quantity, and whether, in your opinion, 
some values are more likely than others. You may have considerable uncertainty about 
some of these quantities (though less than that of a lay person). This will not be of concern 
during the elicitation itself, as the outputs from the elicitation will reflect large uncertainty 
when it is present. 
Due to the subjective nature of elicited probability distributions, it is important to make the 
elicitation process as transparent as possible. A written record will be kept of the meeting, 
ZKLFK ZLOO LQFOXGH GHWDLOV RI H[SHUWV SUHVHQW DW WKH PHHWLQJ D VXPPDU\ RI HDFK H[SHUW¶V
relevant expertise, and any declarations of interest. It would be helpful if you could complete 
sections 2 and 4 in the pro forma. A brief summary will be sufficient for section 4, covering 
expertise relevant to the parameters listed in section 3. 
Please note that declarations of interest are recorded for the purposes of transparency only, 
and will not be used as grounds for exclusion from the elicitation. It is common for experts to 
be stakeholders in the wider process. 
Suggested relevant evidence is listed in section 5. If you wish to add to this list you may do 
so. Where appropriate, publications/data listed in this section will be made available at the 
elicitation meeting. 
Reference: 
O'Hagan, A., Buck, C. E., Daneshkhah, A., Eiser, J. E., Garthwaite, P. H., Jenkinson, D. J., 
Oakley, J. E. and Rakow, T. (2006). Uncertain Judgements: Eliciting Expert Probabilities. 
Chichester: Wiley.  
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Quantifying uptake determinants of Technology A for use in pre-term birth 
screening in the UK 
 
Pre-elicitation meeting pro forma 
 
1) Background The purpose of this exercise is to obtain estimates of future purchases 
for Technolgy A for use in pre-term birth screening. These estimates 
will then be used in an economic evaluation of this device that will 
show future cost-effectiveness and help in setting research priorities. 
2) Declarations of 
interests 
[To be completed by the expert.  Please identify any personal interest 
that you might have in the outcome of this elicitation exercise, or in 
the wider context specified above: these can include being an 
investigator in the trial of Technology A, being involved in the 
development of Technology A, having any stake or interest in the 
economic outcomes of Technology A or future research prospects] 
 
 
 
3) Parameter 
definitions 
1. The number of potential purchases of Technology A in the NHS 
England (your expertise of adoption processes in the NHS in your 
field of work is needed). 
2. The number of years at which the purchase rate peaks (your 
expertise of how long it takes to reach the majority of adopters in the 
NHS in your field of work is needed). 
3. The number of purchases at the peak. 
4. The same 3 parameters as above assuming that there is more 
research available (your expertise of impact of research on adoptions 
in your field of work is needed). 
3DUWLFLSDQW¶V
expertise  
[To be completed by the expert.  Please briefly identify your expertise 
in relation to the parameters listed above.] 
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5) Key relevant 
evidence 
[The expert should add details of any key documents and studies that 
are relevant to the above parameters, if any.] 
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ELICITATION RECORD ± Part 1 ± Context 
To be filled in by the facilitator. 
 
Elicitation title Quantifying factors that will influence usage of a new technology for 
pre-term birth screening in the UK 
Session 1 
Date 
 
Part 1 start time 
 
 
Attendance and 
roles 
 
Purpose of 
elicitation 
To obtain estimates of future adoptions for Technology A in pre-term 
birth with the purpose of performing an economic evaluation 
This record Participants are aware that this elicitation will be conducted using the 
Sheffield Elicitation Framework, and that this document, including 
attachments, will form a record of the session. 
Orientation and 
training 
Conducted on one quantity: the number of pre-term births in one year in 
the NHS England 
3DUWLFLSDQWV¶
expertise  
 
Declarations of 
interests 
 
Strengths and 
weaknesses 
 
Evidence 
 
Structuring 1. maximum number of purchases attainable given current evidence  
2. number of years at which number of purchases peak given current 
evidence  
3. number of purchases at peak given current evidence  
4. maximum number of purchases attainable given availability of further 
evidence  
5. number of years at which number of purchases peak given 
availability of further research evidence  
6. number of purchases at peak given availability of further evidence   
Definitions See structuring 
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1. m1 
2. n1-1 
W¶ 
4. m2 
5. n1-2 
W¶ 
 
Part 1 end time 
 
Attachments 
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ELICITATION RECORD ± Part 2 ± Distribution 
Tertile Method 
Example for one quanitity - to be filled in by the facilitator. 
 
Elicitation title Quantifying factors that will influence usage of a new technology for 
pre-term birth screening in the UK 
Session 1 
Date 
 
Quantity 1. maximum number of purchases attainable given current evidence 
Start time 
 
 
Definition m1 
Evidence As in background sheet 
Plausible range  
Median  
Upper and lower 
tertiles 
 
Fitting 
 
Group elicitation 
- 
Fitting and 
feedback 
 
Chosen 
distribution 
 
Discussion 
 
 
End time 
 
Attachments 
 
 
 
 
 
